On August 3, the United States Court of Appeals for the Federal Circuit (CAFC) denied a petition for rehearing en banc and issued a modified opinion, following a petition for rehearing filed by Ariosa in Illumina, Inc. v. Ariosa Diagnostics, Inc. Sticking closely to the reasoning of its March opinion, the CAFC reversed a decision by the United States District Court for the Northern District of California that claims of U.S. Patent Nos. 9,580,751 (the ’751 patent) and 9,738,931 (the ’931 patent) belonging to Sequenom and Illumina (Illumina) were invalid under 35 U.S.C. § 101 as being directed to an ineligible natural phenomenon.
Illumina v. Ariosa: En Banc Rehearing Denied, Illumina Patents Again Upheld on Rehearing
No Comments
Litigation
- Ericsson Wins Anti-Interference Injunction Against Samsung in Texas FRAND Case
- Supreme Court Will Review Doctrine of Assignor Estoppel
- Patent Filings Roundup: IP Edge End-of-Year Filing Spree, WSOU Ends Year as Top Single-Entity Filer; AC Competitors Go to War Over a Cool Million
- Alice in 2020: Slashing Software Patents and Searching for Functional Language at the Federal Circuit (Part I)
- Inventors Have Their Say on PTAB at SCOTUS in Arthrex Amicus Briefs
Recent Posts
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- From Agent to Examiner and Back Again: Practical Lessons Learned from Inside the USPTO
- Other Barks & Bites for Friday, January 15: Copyright Office Issues Final Rule on Unmatched Musical Works Under MMA, $1 Billion Copyright Verdict Against Cox Communications Upheld, USPTO Publishes Report on China IP Filings
- USPTO Report Puts Chinese Innovation Growth in Context